Michael G. Carter, M.D.

Michael G. Carter, M.D. has been a member of HCR’s SAB since 2009 and Investment Committee since 2015. HCR primarily utilizes Dr. Carter’s skill set in the assessment of product candidates, clinical data and market opportunities. Dr. Carter is a venture partner at SV Health Investors LLP and serves as a non-executive board member of Artios Pharma Ltd. and GTx, Inc.; he has held numerous non-executive director positions over the last two decades including Warner-Chilcott, Micromet, Santarus, Kudos, Oncoethix, Metris Therapeutics, Fulcrum, Cancervax, Atopix Therapeutics and Salick Health Care. Previously, Dr. Carter was a member of the strategic advisory board for the Paul Royalty Funds, the predecessor firm of the founders. From 1984 to 1998, Dr. Carter held numerous positions with Zeneca Pharmaceuticals (now AstraZeneca), including international marketing director, international medical director and serving on that company’s board of directors for 15 years. Dr. Carter also held numerous positions with Roche Products Ltd from 1976 to 1984, including director of the pharmaceutical division, head of medical development and medical affairs, and an adverse reactions physician. For nearly a decade he served on the UK Government’s Medicines Commission and, prior to entering the pharmaceutical industry, was a practicing physician. Dr. Carter holds a Diploma in Pharmaceutical Medicine, an MBChB from Sheffield University Medical School, a B-Pharm from London University’s School of Pharmacy and is a member of the Pharmaceutical Society. He was elected a Fellow of the Royal Pharmaceutical Society, a Fellow of Faculty of Pharmaceutical Medicine of the Royal College of Physicians and a Fellow of the Royal College of Physicians, Edinburgh.